Studies how people with advanced lung cancer are treated first
Reviews medical records of adults with advanced non-small cell lung cancer starting first treatment.
Plain-language title generated from the registry record
Registry title: DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First-line Treatment Patterns
Key facts
- Where
- Recife, Rio de Janeiro, Salvador, and São Paulo, BrazilSee the 4 sites
Where in Brazil
- RecifeRecife, BrazilNo longer taking part
- Rio de JaneiroRio de Janeiro, BrazilTaking people
- SalvadorSalvador, BrazilTaking people
- São PauloSão Paulo, BrazilNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07109154
- Record updated
- 13 May 2026
- Original description
This is a prospective, observational, multicenter study, in which clinical and demographic data will be extracted from medical records. Convenience sample, with an estimated inclusion of 200 patients treated in seven participating centers.Read full original descriptionShow less
DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First-line Treatment Patterns Observational Study (Prospective and Survey); Evaluation Patterns of Choice in First Line Treatment of Metastatic NSCLC
This is a prospective, observational, multicenter study, in which clinical and demographic data will be extracted from medical records. Convenience sample, with an estimated inclusion of 200 patients treated in seven participating centers.
Eligible tumors for this project will be from patients with advanced (unresectable or metastatic) non-small cell lung carcinoma, who will start first-line oncological treatment in one of the participating centers between 2025 and 2026 (between January 2025 and January 2026). Patients must be over 18 years old and data must be available in electronic medical records.
Medical records will be assessed to confirm patients' eligibility. Patients with localized disease amenable to local treatment, non-epithelial histology, small cell carcinoma and neuroendocrine tumor will not be eligible.
A survey will be designed targeting thoracic and generalist medical oncologists, aiming to understand the factors guiding the choice of first-line treatment regimens and to compare these insights with real-world data. The survey will be directed to Brazil, with an estimated of 200 filled files.
Inclusion: Advanced (unresectable or metastatic) non-small cell lung carcinoma; First-line oncological treatment in one of the participating centers between 2025 and 2026 (between January 2025 and January 2026); > 18 years old; Data available in electronic medical records.
Exclusion: Patients with unresectable NSCLC who underwent treatment with the PACIFIC protocol and are being followed up; Localized disease amenable to local treatment; Non-epithelial histology; Small cell carcinoma; Neuroendocrine tumor.